Reporte de caso: Dermatomiositis Juvenil
Keywords:
Dermatomiositis Infantil, Histidina-ARNt Ligasa, Metotrexato.Abstract
La Dermatomiositis Juvenil es una patología de carácter autoinmune, muy poco frecuente, de presentación subaguda-crónica. Afecta a pacientes menores de 16 años, manifestándose con debilidad muscular proximal y lesiones cutáneas características, puede asociarse a trastornos autoinmunes y neoplasias malignas. El objetivo del estudio es exponer un caso con sus manifestaciones clínicas, proceso diagnóstico y tratamiento, con el fin de lograr un diagnóstico oportuno y evitar la morbimortalidad asociada a esta patología. Se presenta paciente femenino de 13 años con debilidad muscular proximal, eritema facial, pápulas de Gottron y astenia. Se instaura tratamiento con metilprednisolona y metotrexato con posterior remisión. El abanico de opciones terapéuticas deberá ser tomado de forma individualizada en cada paciente, tomando en cuenta los criterios de gravedad, con el fin de realizar un manejo conservador o decidir una terapia agresiva para lograr la remisión del cuadro y al mismo tiempo disminuir el riesgo de efectos adversos asociados al tratamiento.
Downloads
References
Gara S, Jamil RT, Muse ME, Litaiem N. Dermatomiositis juvenil. En: StatPearls.Treasure Island (FL): StatPearls Publishing; 2021.Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK534236/
Ledesma A. A propósito de un caso: Dermatomiositis juvenil [Internet]. Revista-ortalesmedicos.com. 2020 [Consultado el 25 de marzo de 2021]. Disponible en: https://www.revista-portalesmedicos.com/revista-medica/a-proposito-de-un-caso-dermatomiositis-juvenil/
Deakin C, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn L, Pullenayegum E, et al. Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. Arthritis Rheumatol [Internet]. 2018;70(5):785–93. doi: 10.1002/art.40418. Available from: https://pubmed.ncbi.nlm.nih.gov/29342499/
Cartas US. Inicio de dermatomiositis juvenil en un escolar de 7 años de edad. Rev cuabana Reumatol [Internet]. 2020;22(3):e749. Available from: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/749
Mena PÁ, Villacís LS, Bautista PB, Pérez VM, Jordán DZ. Revista Cubana de Reumatología Dermatomiositis juvenil . Sistematización de casos. 2019;1–14. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962019000200011
Yoo J, Ahn SS, Jung SM, Song JJ, Park Y, Lee S. Reclassification of Korean patients with polymyo- sitis and dermatomyositis based on the Bohan and Peter criteria by the 2017 European League Against Rheumatism / American College of Rheumatology classification criteria for adult and juvenile idio- pathic. Korean J Intern Med [Internet]. 2021;441–6. doi: 10.3904/kjim.2019.149. Available from: https://pubmed.ncbi.nlm.nih.gov/31875667/
Kwa MC, Silverberg JI, Ardalan K. Inpatient burden of juvenile dermatomyositis among children in the United States. Pediatr Rheumatol [Internet]. 2018;16(1):1–11. doi: 10.1186 / s12969-018-0286-1. Available from: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-018-0286-1
Kishi T, Bayat N, Ward MM, Huber M, Wu L, Mamyrova G, et al. Medications received by patients with juvenile dermatomyositis. 2019;48(3):513–22. doi: 10.1016 / j.semarthrit.2018.03.016. Available from: https://pubmed.ncbi.nlm.nih.gov/29773230/
Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pediatr [Internet]. 2018;6(October):1–8. doi: 10.3389 / fped.2018.00284. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189418
Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis [Internet]. 2017;76(2):329–40. doi: 10.1136/annrheumdis-2016-209247. Available from: https://pubmed.ncbi.nlm.nih.gov/27515057/
Gupta P, Shruti S, Chaudhary V, Khullar G, Siraj F. Juvenile Dermatomyositis: A Case Report and Review of Literature. Cureus [Internet]. 2019;11(1):1–8. doi: 10.7759 / cureus.3935 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433086/
Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: Latest advances. Best Pract Res Clin Rheumatol [Internet]. 2017;31(4):535–57. doi: 10.1016 / j.berh.2017.12.003. Available from: https://doi.org/10.1016/j.berh.2017.12.003
Tseng CC, Chang SJ, Tsai WC, Ou TT, Wu CC, Sung WY, et al. Sex differential association of dermatomyositis with Sjögren syndrome. Cmaj [Internet]. 2017;189(5):E187–93. doi: 10.1503 / cmaj.160783. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289869/
Wienke J, Deakin CT, Wedderburn LR, van Wijk F, van Royen-Kerkhof A. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Front Immunol [Internet]. 2018;9(December):2951. doi: 10.3389 / fimmu.2018.02951Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305419/
Wakiguchi H. Multispecialty approach for improving outcomes in juvenile dermatomyositis. J Multidiscip Healthc [Internet]. 2019;12:387–94. doi: 10.2147 / JMDH.S171095. Available from: https://pubmed.ncbi.nlm.nih.gov/31213823/
Hinze CH, Speth F, Oommen PT, Haas JP. Current management of juvenile dermatomyositis in Germany and Austria: An online survey of pediatric rheumatologists and pediatric neurologists. Pediatr Rheumatol [Internet]. 2018;16(1):1–8. doi: 10.1186/s12969-018-0256-7 Available from: https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-018-0256-7
Miquel CA De. Tratamiento con rituximab en dermatomiositis juvenil. Efecto sobre la calcinosis. 2020;16(5):2009–11. doi: 10.1016/j.reuma.2018.06.010 Available from: https://www.reumatologiaclinica.org/es-tratamiento-con-rituximab-dermatomiositis-juvenil--articulo-S1699258X18301281
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
